Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study

What Was Tested

Researchers studied Bombesin in this clinical trial, phase ii publication.

The bombesin derivative RM2 is a GRPr antagonist with strong binding affinity to prostate cancer (PCa).

In this study, the impact of [68Ga]Ga-RM2 positron emission tomography-computed tomography (PET-CT) for the detection of primary PCa was compared with that of [18F]FCH PET-CT and multiparametric magnetic resonance imaging (mpMRI).

Who Took Part

According to the abstract, 10 patients were involved.

PubMed tags the participants as men only.

This phase I/II study was conducted in 30 biopsy-positive PCa subjects.

The patients were stratified into high (10 patients), intermediate (10 patients), and low risk (10 patients) for extraglandular metastases as defined by National Comprehensive Cancer Network (NCCN) criteria (NCCN Clinical Practice Guidelines in Oncology, 2016).

How the Study Was Run

The prostate gland was classified in 12 anatomic segments for data analysis of the imaging modalities as well as histopathologic findings.

The segment with the highest radiotracer uptake was defined as the "index lesion." All cases were scheduled to undergo prostatectomy with pelvic lymph node (LN) dissection in intermediate- and high-risk patients.

Intraprostatic and pelvic nodal [68Ga]Ga-RM2 and [18F]FCH PET-CT findings were correlated with mpMRI and histopathologic results.

What Was Measured

The subject headings attached to it are Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography Computed Tomography, Gallium Radioisotopes, Bombesin, Choline and Prostatic Neoplasms.

The authors tagged it with the keywords PET-CT, Prostate cancer, [18F]FCH, [68Ga]Ga-RM2 and mpMRI.

What This Means in Plain Language

This is a clinical trial, phase ii of Bombesin in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (European radiology), a journal based in Germany.

More context: the Bombesin compound page, all human trials.